937633-19-7

Basic information

• Product Name: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole
• Synonyms: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole
• CAS NO: 937633-19-7
• Molecular Formula: C9H5ClF2N2O
• Molecular Weight: 230.5986064
• Mol File: 937633-19-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(937633-19-7)
• EPA Substance Registry System: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(937633-19-7)

Safety Data

• Hazardous Substances Data: 937633-19-7(Hazardous Substances Data)

Usage

General Description

2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole is a chemical compound with the molecular formula C9H6ClF2N3O. It is a heterocyclic compound containing an oxadiazole ring and is derived from 2,4-difluorobenzonitrile. 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole has potential applications in the field of medicinal chemistry and pharmaceuticals due to its biological activities. It has been studied for its potential as an anticancer and antiviral agent, and for its ability to inhibit enzymes such as the human Pin1 protein. Further research is needed to fully understand the properties and potential uses of 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole.

Upstream product

• 118737-62-5 2,4-difluorobenzoic acid hydrazide 
• 79-11-8 chloroacetic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 

Relevant articles and documents

Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer's disease

Novel N-Benzylpyrrolidine hybrids were designed, synthesized, and tested against multiple in-vitro and in-vivo parameters. Among all the synthesized molecules, 8f and 12f showed extensive inhibition against beta-secretase-1 (hBACE-1), human acetylcholinesterase (hAChE) & human butyrylcholinesterase (hBuChE). These molecules are also endowed with significant AChE-peripheral anionic site (PAS) binding capability, blood-brain barrier permeability, potential disassembly of Aβ aggregates along with neuroprotection ability on SHSY-5Y cell lines. Results of the Y-Maze and Morris water maze test concluded that compounds 8f and 12f ameliorated cognitive dysfunction induced by scopolamine and Aβ. The ex-vivo activity was executed on rat's brain homogenate indicating a reduction in AChE level and oxidative stress. The pharmacokinetic investigation ascertained considerable oral absorption profile of the lead 12f. The results of the in silico docking studies and molecular dynamics simulations demonstrated stable interactions of compounds 8f and 12f with the target residues of hAChE, hBuChE and hBACE-1.